SKIN — Stock Film
STOCK FILMSCENE 1/11SKIN · $0.68
Stock Expert AI presents
SKIN
SkinHealth Systems Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
SkinHealth Systems Inc. What it actually does.

Designs and develops aesthetic technologies. Manufactures aesthetic treatment systems. Now — the numbers.

on the stock market since 2020
613 employees
$88.1M market value
WHERE DOES THE MONEY COME FROM?
71%Consumables
ConsumablesDelivery Systems 29%
71% of all revenue comes from a single line: Consumables.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Revenue last year:
$300.8M
The loss that same year:
$9.5M
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$232.7M
DEBT: $378.7M
At this pace, that money lasts about 24.4 years.

At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.

THE PRICE TAG
MARKET VALUE / ANNUAL SALES
0.3×

This company is not turning a profit, so the market is pricing its sales instead: 0.3× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 75% of them.

Analysts' average target sits 121% above today's price.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
75
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
14
very weak

Clearly below the class average.

VALUATION
75
strong

Clearly above the class average — a step short of the very top.

GROWTH
71
strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
23
very weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
The product is selling

Sales run at $300.8M a year. A small number, but proof the product has real buyers.

1
THE RISKS · 1/2
Small scale, thin loss

A loss of $9.5M against $300.8M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
Trading under $1

The stock sits at $0.68. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

FINALE · THE GRADE
F
25 / 100 · MoonshotScore

On our five-subject report card, SKIN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: SKIN is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Sep 10, 2026 · stockexpertai.com · Stock Film